AMSBIO has introduced a series of kit products based upon high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
These new kit products include SARS-CoV-2 inhibitor screening kits, antibody titer serologic assay kits, antigen detection kit and antigen pre-coated plates.
SARS-CoV-2 is an enveloped positive-stranded RNA virus that consists of four structural proteins including spike glycoprotein, envelope protein, membrane protein, and nucleocapsid protein. Researchers have identified the spike glycoprotein as the most important surface protein of SARS-CoV-2, which can mediate the virus entry into human respiratory epithelial cells by interacting with cell surface receptor angiotensin-converting enzyme 2 (ACE2). Spike S and S1 RBD proteins are important targets in the development of SARS-COV-2 therapeutics and vaccines.
The versatile SARS-CoV-2 inhibitor kit can be used to reproducibly screen small molecule inhibitors, polypeptide inhibitors and neutralizing antibodies specifically, efficiently and rapidly. Available in package sizes of 96 tests and 480 tests make the simultaneous screening of a large number of samples quick and easy.
Combining high specificity, sensitivity and reproducibility – AMSBIO has also introduced a range of titer IgG, IgM, total antibody and total protective neutralizing antibody titer assay kits. These SARS-CoV-2 antibody titer assay kits can be used to verify the effectiveness of vaccines by detecting the antibody titer, and also to evaluate the scientific research of antibody titer in infected patients. The results of neutralizing antibody titer indicate its neutralizing ability, which can be used as one of the criterions for antibody assessment.
Employing a double antibody sandwich method to detect SARS-COV-2 antigen protein, the new S1 antigen and N antigen assay kits provide a highly sensitive way to determine viral infection status and guide the design of vaccine development.
To reproducibly quantify anti-SARS-COV-2 antibodies or ACE2 protein with high sensitivity, AMSBIO offer a range of 96-well antigen plates precoated with Spike S1 and S RBD protein. Designed in an ANSI/SLAS standard format these microplates are fully compatible with high throughput automation systems
For further information on the new SARS-CoV-2 antigen protein kit range please visit https://www.amsbio.com/covid-19-antibody-antigen-titer-assay-kits/ or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / [email protected].
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.
